Showing 1 - 20 of 77 Items
Showing 1 - 20 of 77 Items
Sort By: Relevance
Journal Article
|Review
2024-05-01 • International Health
2024-05-01 • International Health
BACKGROUND
We performed a systematic review to generate evidence on the association between cumulative human immunodeficiency virus (HIV) viraemia and health outcomes.
METHO...
We performed a systematic review to generate evidence on the association between cumulative human immunodeficiency virus (HIV) viraemia and health outcomes.
METHO...
Journal Article
|Research
2024-02-01 • Lancet Respiratory Medicine
2024-02-01 • Lancet Respiratory Medicine
BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...
Journal Article
|Case Report/Series
2024-01-09 • Clinical Infectious Diseases
2024-01-09 • Clinical Infectious Diseases
BACKGROUND
HIV patients with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas with anthroponotic transmission such as East-Africa, but s...
HIV patients with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas with anthroponotic transmission such as East-Africa, but s...
Journal Article
|Protocol
2023-12-14 • BMJ Open
2023-12-14 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30,000 new cases occurring annually. Despite anaemia being a common haematological manifestation of ...
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30,000 new cases occurring annually. Despite anaemia being a common haematological manifestation of ...
Journal Article
|Protocol
2023-10-28 • BMJ Open
2023-10-28 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. There is an observed variation in the efficacy of the current f...
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. There is an observed variation in the efficacy of the current f...
Journal Article
|Research
2023-10-27 • PLOS Neglected Tropical Diseases
2023-10-27 • PLOS Neglected Tropical Diseases
INTRODUCTION
Noma is a rapidly spreading infection of the oral cavity which mainly affects young children. Without early treatment, it can have a high mortality rate. Simple gingivit...
Noma is a rapidly spreading infection of the oral cavity which mainly affects young children. Without early treatment, it can have a high mortality rate. Simple gingivit...
Journal Article
|Editorial
2023-10-19 • Pathogens
2023-10-19 • Pathogens
Human African trypanosomiasis (also known as sleeping sickness, with Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense as etiological agents), American trypanosomiasis (als...
Journal Article
|Research
2023-09-20 • Journal of Antimicrobial Chemotherapy
2023-09-20 • Journal of Antimicrobial Chemotherapy
OBJECTIVES
To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated...
To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated...
Conference Material
|Slide Presentation
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|Abstract
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The parasitic disease visceral leishmaniasis (VL) is most commonly caused by Leishmania donovani in eastern Africa, currently the region with highest burden worldwide. C...
The parasitic disease visceral leishmaniasis (VL) is most commonly caused by Leishmania donovani in eastern Africa, currently the region with highest burden worldwide. C...
Journal Article
|Commentary
2023-03-23 • PLOS Neglected Tropical Diseases
2023-03-23 • PLOS Neglected Tropical Diseases
Journal Article
|Commentary
2022-12-21 • Toxicon: X
2022-12-21 • Toxicon: X
The medical humanitarian organization Médecins Sans Frontières (MSF) provides medical care in more than 70 countries and admits more than 7000 cases of snakebite in its facilities each y...
Journal Article
|Research
2018-02-22 • American Journal of Tropical Medicine and Hygiene
2018-02-22 • American Journal of Tropical Medicine and Hygiene
Early diagnosis and treatment is the principal strategy to control visceral leishmaniasis (VL), or kala-azar in East Africa. As VL strikes remote rural, sparsely populated areas, kala-az...
Journal Article
|Research
2017-06-05 • PLOS One
2017-06-05 • PLOS One
BACKGROUND
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A clinical prognostic score for death in VL patients could contribute to...
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A clinical prognostic score for death in VL patients could contribute to...
Journal Article
|Research
2019-10-07 • American Journal of Tropical Medicine and Hygiene
2019-10-07 • American Journal of Tropical Medicine and Hygiene
Cutaneous leishmaniasis (CL), a neglected parasitic skin disease, is endemic in Pakistan, where Leishmania tropica and Leishmania major are the causative protozoan species. Standard trea...
Journal Article
|Research
2009-06-01 • American Journal of Tropical Medicine and Hygiene
2009-06-01 • American Journal of Tropical Medicine and Hygiene
Accuracy of an rK39 rapid diagnostic test (DiaMed-IT-Leish ) for visceral leishmaniasis (VL) was compared with splenic aspiration and the direct agglutination test (DAT) in a population ...
Journal Article
|Research
2014-06-26 • PLOS Neglected Tropical Diseases
2014-06-26 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL) is an important protozoan opportunistic disease in HIV patients in endemic areas. East Africa is second to the Indian subcontinent in the global VL caseload a...
Journal Article
|Research
2007-01-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2007-01-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
In Sudan, two treatments are currently registered for visceral leishmaniasis: sodium stibogluconate (SSG) as first line and liposomal amphotericin B (AmBisome) as second line. We present...
Journal Article
|Research
2014-03-21 • Public Health Action
2014-03-21 • Public Health Action
SETTING
Two subdistricts in Bangladesh, Fulbaria and Trishal, which are hyperendemic for leishmaniasis.
OBJECTIVE
To determine 1) the numbers of patients diagnosed with ...
Two subdistricts in Bangladesh, Fulbaria and Trishal, which are hyperendemic for leishmaniasis.
OBJECTIVE
To determine 1) the numbers of patients diagnosed with ...
Journal Article
|Research
2018-05-25 • PLOS Neglected Tropical Diseases
2018-05-25 • PLOS Neglected Tropical Diseases
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and...